ITIF: China Poses Competitive Threat To U.S. Pharma, Could Lower Prices

Generic drug makers in the United States could experience an uptick in competition from China in the next 10 years, according to a non-profit think tank that focuses on public policy and innovation. Though that might not be good news for U.S. drug companies, especially if they continue to face potential intellectual property (IP) theft and hacking by the Chinese, the think tank argues that if China can improve its regulatory and approval system and cut back on “unfair, mercantilist”...